$NVLX > > > When Nuvilex, Inc. (OTCQB: NVLX) announced that it had contracted Inno Biologics to generate cell clones that will be the basis of the company's future Phase III clinical trials in advanced, inoperable, pancreatic cancer, many investors may not have realized this is the most vital step in the process of beginning the company's future late-stage clinical trials next to the actual enrollment of patients. Nuvilex's success in its future trials, and quite frankly its future in general, will be pinned on its recently acquired live-cell encapsulation based treatments. $NVLX Website: